OBJECTIVES: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. DESIGN: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. METHODS: Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. RESULTS: The majority of participants (N = 768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P < 0.001) and adherence strata [Cochran-Mantel-Haenszel P < 0.001; <60% adherence, hazard ratio 1.7 (1.1-2.7), P = 0.02; 60-79% adherence, hazard ratio 1.2 (0.5-3.2), P = 0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P = 0.06; ≥95% adherence, hazard ratio 3.6 (2.3-5.6), P < 0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. CONCLUSIONS: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.
OBJECTIVES: To evaluate the risk of virologic failure conferred by suboptimal adherence to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and minority NNRTI resistance mutations. DESIGN: Pooled analysis of the risk of virologic failure conferred by minority NNRTI resistance mutations and NNRTI adherence from three studies of treatment-naïve individuals initiating an NNRTI-based regimen. METHODS:Participants from each study were categorized into both adherence quartiles (Q1-Q4) and four strata: at least 95%, 80-94%, 60-79%, and below 60%. Weighted Cox proportional hazard models were used to estimate the risk of virologic failure. RESULTS: The majority of participants (N = 768) had high measured adherence, but those in the lowest adherence quartile had the highest proportion of participants with virologic failure and the risk of virologic failure increased step-wise with adherence below 95%. Detection of minority NNRTI drug resistance mutations increased the proportion of participants with virologic failure across adherence quartiles (Cochran-Mantel-Haenszel P < 0.001) and adherence strata [Cochran-Mantel-Haenszel P < 0.001; <60% adherence, hazard ratio 1.7 (1.1-2.7), P = 0.02; 60-79% adherence, hazard ratio 1.2 (0.5-3.2), P = 0.67; 80-94% adherence, hazard ratio 2.5 (0.98-6.3), P = 0.06; ≥95% adherence, hazard ratio 3.6 (2.3-5.6), P < 0.001]. On multivariate analysis, the effect of minority variants was also most prominent at higher levels of medication adherence. CONCLUSIONS: The presence of minority NNRTI resistance mutations and NNRTI adherence were found to be independent predictors of virologic failure, but also modify each other's effects on virologic failure. In addition to the focus on medication adherence counseling, ultrasensitive HIV-1 drug resistance assays could play a role in optimizing the success rates of first-line antiretroviral therapy.
Authors: James A McKinnell; James H Willig; Andrew O Westfall; Christa Nevin; Jeroan J Allison; James L Raper; Michael J Mugavero; Michael S Saag Journal: AIDS Patient Care STDS Date: 2010-02 Impact factor: 5.078
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Christina Lalama; Bruce R Schackman; William A Meyer; Edward P Acosta; Jeffrey Schouten; Kathleen E Squires; Christopher D Pilcher; Robert L Murphy; Susan L Koletar; Margrit Carlson; Richard C Reichman; Barbara Bastow; Karin L Klingman; Daniel R Kuritzkes Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Karin J Metzner; Michael J Kozal; Kathy Huppler Hullsiek; Melanie Balduin; Martin R Jakobsen; Anna Maria Geretti; Rodolphe Thiebaut; Lars Ostergaard; Bernard Masquelier; Jeffrey A Johnson; Michael D Miller; Daniel R Kuritzkes Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Suely H Tuboi; Mauro Schechter; Catherine C McGowan; Carina Cesar; Alejandro Krolewiecki; Pedro Cahn; Marcelo Wolff; Jean W Pape; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Daniel R Masys; Bryan E Shepherd Journal: J Acquir Immune Defic Syndr Date: 2009-08-15 Impact factor: 3.731
Authors: Roger Paredes; Christina M Lalama; Heather J Ribaudo; Bruce R Schackman; Cecilia Shikuma; Francoise Giguel; William A Meyer; Victoria A Johnson; Susan A Fiscus; Richard T D'Aquila; Roy M Gulick; Daniel R Kuritzkes Journal: J Infect Dis Date: 2010-03 Impact factor: 5.226
Authors: Keri N Althoff; Kelly A Gebo; Stephen J Gange; Marina B Klein; John T Brooks; Robert S Hogg; Ronald J Bosch; Michael A Horberg; Michael S Saag; Mari M Kitahata; Joseph J Eron; Sonia Napravnik; Sean B Rourke; M John Gill; Benigno Rodriguez; Timothy R Sterling; Steven G Deeks; Jeffrey N Martin; Lisa P Jacobson; Gregory D Kirk; Ann C Collier; Constance A Benson; Michael J Silverberg; James J Goedert; Rosemary G McKaig; Jennifer Thorne; Anita Rachlis; Richard D Moore; Amy C Justice Journal: AIDS Res Ther Date: 2010-12-15 Impact factor: 2.250
Authors: Valerie F Boltz; Yajing Bao; Shahin Lockman; Elias K Halvas; Mary F Kearney; James A McIntyre; Robert T Schooley; Michael D Hughes; John M Coffin; John W Mellors Journal: J Infect Dis Date: 2014-01-16 Impact factor: 5.226
Authors: Ingrid A Beck; Wenjie Deng; Rachel Payant; Robert Hall; Roger E Bumgarner; James I Mullins; Lisa M Frenkel Journal: J Clin Microbiol Date: 2014-04-16 Impact factor: 5.948
Authors: Russell B Van Dyke; Kunjal Patel; Ron M Kagan; Brad Karalius; Shirley Traite; William A Meyer; Katherine K Tassiopoulos; George R Seage; Lorna M Seybolt; Sandra Burchett; Rohan Hazra; Robert H Lurie; Ram Yogev; Margaret Ann Sanders; Kathleen Malee; Scott Hunter; William Shearer; Mary Paul; Norma Cooper; Lynnette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Patricia Garvie; James Blood; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Andrew Wiznia; Marlene Burey; Molly Nozyce; Arry Dieudonne; Linda Bettica; Susan Adubato; Janet Chen; Maria Garcia Bulkley; Latreaca Ivey; Mitzie Grant; Katherine Knapp; Kim Allison; Megan Wilkins; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Medea Jones; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Alisa Katai; Jennifer Dunn; Suzanne Paul; Gwendolyn Scott; Patricia Bryan; Elizabeth Willen Journal: Clin Infect Dis Date: 2016-04-07 Impact factor: 9.079
Authors: Seth C Kalichman; Tamar Grebler; Christina M Amaral; Megan McNerey; Denise White; Moira O Kalichman; Chauncey Cherry; Lisa Eaton Journal: J Gen Intern Med Date: 2012-10-12 Impact factor: 5.128